The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA